Foundayo begins shipping through LillyDirect

Eli Lilly began shipping Foundayo (orforglipron), its once-daily oral GLP-1 for chronic weight management, through the company's LillyDirect channel on April 6, 2026 ^[1][3]. The FDA approved the pill on April 1, and Lilly accepted prescriptions through LillyDirect immediately, with broad availability at U.S. retail pharmacies and telehealth providers following on April 9 ^[1][5].

What it costs

Lilly says eligible people with commercial insurance that covers Foundayo may pay as little as $25 per month using the Foundayo savings card ^[1][2]. For people paying cash, the company lists a dose-by-dose self-pay price ladder on its LillyDirect page: $149 a month for the 0.8 mg starting dose, $149 for 2.5 mg, $199 for 5.5 mg, and $299 for 9 mg ^[2]. The two highest doses, 14.5 mg and 17.2 mg, are listed at $299 a month through Lilly's Self-Pay Journey Program, with regular prices applying if the prescription is not refilled within 45 days ^[2]. Lilly also notes that the 2.5 mg and 5.5 mg prices are temporarily reduced through December 31, 2026 ^[2]. All of the self-pay terms are described as "NOT INSURANCE," require a prescription, and may carry additional taxes and fees ^[2].

LillyDirect is Lilly's direct-to-patient pharmacy setup. It does not fill prescriptions itself; it works with four dispensing pharmacies — Amazon Pharmacy, Fuze Health, Gifthealth and Walmart Pharmacy — and which one handles an order depends on the medicine, delivery method and payment method ^[2]. Patients can choose free home delivery or free pickup at a retail pharmacy, and Lilly says it will check commercial coverage and help with prior authorization when insurance is used ^[2].

Early prescription numbers

Foundayo was prescribed 1,390 times in the U.S. in its first week of sales, according to analysts citing IQVIA data for the week ended April 10 ^[5][6]. Analysts said that figure likely reflects only about two days of data capture ^[5][6]. By comparison, Novo Nordisk's oral Wegovy (semaglutide) reached 3,071 U.S. prescriptions in its first four days after launching January 5, and was prescribed 113,354 times in the week ended April 10, up from 105,366 the prior week ^[5].

Lilly told Reuters the early weekly figures are not fully comprehensive, may not capture all pharmacy partners, and are "best interpreted over time rather than as a complete count" ^[5]. RBC Capital Markets analyst Trung Huynh said weeks 8 through 12 are "the earliest window to assess Foundayo's true commercial momentum" ^[5].

Why it matters for patients

The practical change is channel and format, not just price. Foundayo is a tablet that can be taken at any time of day without food or water restrictions, which removes the fasting-and-waiting routine required by some other oral options ^[1][2]. Lilly CEO David Ricks framed the pill as a lower-intensity option, saying at a conference that it is "not as good as Zepbound or Mounjaro, but can meet the needs of a lot of people" ^[5].

The headline numbers come from different places, so the details matter. In ATTAIN-1, participants on the highest dose who stayed on treatment lost an average of 27.3 pounds (12.4%), versus 2.2 pounds (0.9%) on placebo; counting everyone regardless of whether they finished the trial, the average was 25 pounds (11.1%) versus 5.3 pounds (2.1%) ^[1].

Foundayo carries a warning that it may cause thyroid tumors, including thyroid cancer, and is not recommended with other GLP-1 medicines ^[1]. Common side effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache and hair loss ^[1]. Lilly also notes oral birth control pills may not work as well while taking it ^[1].

What happens next

Lilly says eligible Medicare Part D patients may be able to get Foundayo for $50 per month beginning as soon as July 1, 2026 ^[1]. That lines up with a federal pricing agreement under which Medicare starts covering weight-loss drugs for eligible beneficiaries July 1, 2026, capping the monthly Medicare price for Ozempic, Wegovy, Mounjaro and Zepbound at $245 with a $50 copay ^[4]. How many commercial plans add Foundayo to their formularies — and on what terms — is not yet known from these sources.